1. p53 Inactivation is a Rare Event in Familial Breast Tumors Negative for BRCA1 and BRCA2 Mutations

   • Elisa Sensi
   • Mariella Tancredi
   • Maria A. Caligo

   OriginalPaper Pages: 1 - 9

2. E2F1 Expression is Related with the Poor Survival of Lymph Node-positive Breast Cancer Patients Treated with Fluorouracil, Doxorubicin and Cyclophosphamide

   • Sehwan Han
   • Kyeongmee Park
   • Hong-Yong Kim

   OriginalPaper Pages: 11 - 16

3. Familial Breast Cancer: Scope for More Susceptibility Genes?

   • Kari Hemminki
   • Charlotta Granström

   OriginalPaper Pages: 17 - 22

4. Analysis of HER2 and HER4 in Human Myocardium to Clarify the Cardiotoxicity of Trastuzumab (Herceptin™)

   • Ilka B. Fuchs
   • Solveig Landt
   • Gerhard Schaller

   OriginalPaper Pages: 23 - 28

5. Perioperative Screening for Metastatic Disease is not Indicated in Patients with Primary Breast Cancer and no Clinical Signs of Tumor Spread

   • Bernd Gerber
   • Eva Seitz
   • Klaus Friese

   OriginalPaper Pages: 29 - 37

6. Predictive Factors for the Status of Non-sentinel Nodes in Breast Cancer Patients with Tumor Positive Sentinel Nodes

   • Vincent van Iterson
   • Marjut Leidenius
   • Karl von Smitten

   OriginalPaper Pages: 39 - 45

7. Keeping Data Continuous when Analyzing the Prognostic Impact of a Tumor Marker: An Example with Cathepsin D in Breast Cancer

   • N. Bossard
   • F. Descotes
   • J. Estève

   OriginalPaper Pages: 47 - 59

8. Phase I Trial of Uracil–Ftorafur, Leucovorin, and Etoposide: An Active All-oral Regimen for Metastatic Breast Cancer

   • Anne-Renee Hartman
   • Amy Grekowicz
   • Frank E. Stockdale

   OriginalPaper Pages: 61 - 69

9. Instructions for Authors

   Instructions for Authors Pages: 71 - 74